Access to Investigational Therapies

Duke Street Bio Ltd. is developing the next generation of molecules targeting DNA Damage Repair (DDR) deficiencies to advance care for people with cancer. Our most advanced program is DSB2455, a highly selective PARP1 enzyme inhibitor, for the treatment of patients with solid tumors harboring BRCA1/2 and/or other homologous recombination deficiency (HRD) (Study to Assess Safety, Tolerability and Activity of DSB2455 in Participants With Advanced Malignancies).

We take our commitment to the patients we serve very seriously and strive to develop new treatments as fast as possible. We believe that clinical trials are the most effective way for patients to access investigational products, as clinical trials generate data that may lead to the approval of new medicines and broader availability to patients.

At this time, we are unable to offer an expanded access program for any of our investigational therapies. We will continue to evaluate the possibility of expanded access and update our policy if our position changes.
Should patients or healthcare providers require additional information about the status of our investigational therapies, please do not hesitate to contact Duke Street Bio by email at clinicaltrials@dukesb.com.